Activity of hydroxyurea against Leishmania mexicana

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3642-3647

  Martinez Rojano, Hugo ^a,b   Mancilla Ramirez, Javier ^a,c   Quiñonez Diaz, Laura ^a,d   Galindo Sevilla, Norma ^c  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^d UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; MEGLUMINE ANTIMONATE;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL CYCLE; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYUREA; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MALE; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS;

EID: 54049094432     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00124-08     Document Type: Article

References (34)

1. Alvino, G. M., D. Collingwood, J. M. Murphy, J. Delrow, B. J. Brewer, and M. K. Raghuraman. 2007. Replication in hydroxyurea: it's a matter of time. Mol. Cell. Biol. 27:6396-6406.
2. Berman, J. D. 1997. Human leishmaniasis: clinical diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
3. Blum, J., P. Desjeux, E. Schwartz, B. Beck, and C. Hatz. 2004. Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother. 53:158-166.
4. Bundy, R., N. Marczin, A. H. Chester, and M. Yacoub. 1999. Differential regulation of DNA synthesis by nitric oxide and hydroxyurea in vascular smooth muscle cells. Am. J. Physiol. 277:H1799-H1807.
5. Burkitt, M. J., and A. Raafat. 2006. Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood 107:2219-2222.
6. Callahan, H. L., A. C. Portal, R. Devereaux, and M. Grogl. 1997. An axenic amastigote system for drug screening. J. Antimicrob. Chemother. 41:818-822.
7. Calvopina, M., E. A. Gomez, H. Sindermann, P. J. Cooper, and Y. Hashiguchi. 2006. Relapse of New World diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am. J. Trop. Med. Hyg. 75:1074-1077.
8. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
9. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
10. Cruz, I., J. Nieto, J. Moreno, C. Cañavate, P. Desjeux, and J. Alvar. 2006. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 123:357-388.
11. Di Giorgio, C., F. Delmas, N. Filloux, M. Robin, L. Seferian, N. Azas, M. Gasquet, M. Costa, P. Timon-David, and J. Galy. 2003. In vitro activities of 7-substituted 9-chloro and 9-amino-2-methoxyacridines and their bis- and tetra-acridine complexes against Leishmania infantum. Antimicrob. Agents Chemother. 47:174-180.
12. Dresemann, G. 2005. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. 16:1702-1708.
13. Elford, H. L., G. L. Wampler, and B. van't Riet. 1979. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res. 39:844-851.
14. Ephros, M., A. Bitnun, P. Shaked, E. Waldman, and D. Zilberstein. 1999. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob. Agents Chemother. 43:278-282.
15. Galindo-Sevilla, N., N. Soto, J. Mancilla, A. Cerbulo, E. Zambrano, R. Chavira, and J. Huerto. 2007. Low serum levels of dehydroepiandrosterone and cortisol in human diffuse cutaneous leishmaniasis by Leishmania mexicana. Am. J. Trop. Med. Hyg. 76:566-572.
16. Grolg, M., T. N. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
17. Gwilt, P. R., K. K. Manouilov, J. McNabb, and S. S. Swindells. 2003. Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. J. Clin. Pharmacol. 43:1003-1007.
18. Holland, P. K., L. H. Elford, V. Bracchi, G. C. Annis, M. S. Schuster, and D. Chakrabarti. 1998. Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives. Antimicrob. Agents Chemother. 42:2456-2458.
19. 1/S in Saccharomyces cerevisiae. J. Biol. Chem. 278:9345-9352.
20. Koç, A., L. J. Wheeler, C. K. Mathews, and G. F. Merrill. 2004. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J. Biol. Chem. 279:223-230.
21. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
22. Mesa-Valle, C. M., J. Castilla-Calvente, M. Sanchez-Moreno, V. Moraleda-Lindez, J. Barbe, and A. Osuna. 1996. Activity and mode of action of acridine compounds against Leishmania donovani. Antimicrob. Agents Chemother. 40:684-690.
23. Neal, R. A., and S. L. Croft. 1984. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
24. Rodriguez, G. I., J. G. Kuhn, G. R. Weiss, S. G. Hilsenbeck, J. R. Eckardt, A. Thurman, D. A. Rinaldi, S. Hodges, D. D. Von Hoff, and E. K. Rowinsky. 1998. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533-1541.
25. Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. J. Antimicrob. Chemother. 42:3097-3102.
26. Shao, J., B. Zhou, B. Chu, and Y. Yen. 2006. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6:409-431.
27. Sogo, J. M., M. Lopes, and M. Foiani. 2002. Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects. Science 297:599-602.
28. Soto, J., B. A. Arana, J. Toledo, N. Rizzo, J. C. Vega, A. Diaz, M. Luz, P. Gutierrez, M. Arboleda, J. D. Berman, K. Junge, J. Engel, and H. Sindermann. 2004. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38:1266-1272.
29. Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O. 83:394-395.
30. Villani, P., R. Maserati, M. B. Regazzi, R. Giacchino, and F. Lori. 1996. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J. Clin. Pharmacol. 36:117-121.
31. Wanasen, N., C. L. MacLeod, L. G. Ellies, and L. Soong. 2007. L-Arginine and cationic amino acid transporter 2B regulate growth and survival of Leishmania amazonensis amastigotes in macrophages. Infect. Immun. 75:2802-2810.
32. Wolday, D., N. Berhe, H. Akuffo, and S. Britton. 1999. Leishmania-HIV interaction: immunopathogenic mechanism. Parasitol. Today 15:182-187.
33. Yardley, V., S. L. Croft, S. De Doncker, J. Dujardin, S. Koirala, S. Rijal, C. Miranda, A. Llanos-Cuentas, and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73:272-275.
34. Zick, A., I. Onn, R. Bezalel, H. Margalit., and J. Shlomai. 2005. Assigning functions to genes: identification of S-phase expressed genes in Leishmania major based on transcriptional control elements. Nucleic Acids Res. 33:4235-4242.